Evidence map›Paper›PMID 31895800›Full record

Observational studyMedicine2020

An investigation into the avoidability of adverse drug reactions using the LAAT and modified Hallas tools.

Mohammed Ibn-Mas'ud Danjuma, Shaikha Al Shokri, Ibrahim Y Abubeker, Ashraf El Malik, Ibtihal Mahmoud Hassan Abdallah, Mohamed Nabil El Shafei, Haajra Fatima, Mohamed Mahmoud, Tanweer Hussain, Yahya Maghoub and 2 more

Abstract readObservational Study
In one paragraph

Observational study in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mohammed Ibn-Mas'ud DanjumaWeill Cornell Affiliated-Hamad General Hospital, Hamad Medical Corporation; Weill Cornell Medicine; College of Medicine, Qatar University.
Shaikha Al ShokriDivision of General Internal Medicine, Weill Cornell Affiliated-Hamad General Hospital, Hamad Medical Corporation.
Ibrahim Y AbubekerUnity Internal Medicine Rochester Regional Health New York.
Ashraf El MalikEmergency Department, Weill Cornell affiliated-Hamad General Hospital, Hamad Medical Corporation.
Ibtihal Mahmoud Hassan AbdallahWeill Cornell Affiliated-Hamad General Hospital, Hamad Medical Corporation.
Mohamed Nabil El ShafeiClinical Pharmacist, Weill Cornell affiliated-Hamad General Hospital, Hamad Medical Corporation.
Haajra FatimaWeill Cornell Affiliated-Hamad General Hospital, Hamad Medical Corporation.
Mohamed MahmoudWeill Cornell affiliated-Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Tanweer HussainDivision of General Internal Medicine, Weill Cornell affiliated-Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar; Acute Medicine Unit, Derbyshire Hospitals Foundation Trust, Derby, England, United Kingdom.
Yahya MaghoubWirral University Teaching Hospital NHS Foundation Trust, Liverpool, United Kingdom.
Jamal SajidWeill Cornell Affiliated-Hamad General Hospital, Hamad Medical Corporation.
Abdel Naser El ZoukiHamad General Hospital, Hamad Medical Corporation (HMC), Doha, Qatar, Department of Clinical Sciences, College of Medicine, Qatar University, Weill Cornell Medical College of Qatar, Doha, Qatar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An adverse drug reactions avoidability tool called the Liverpool ADR avoidability assessment tool (LAAT) was recently developed (for research purposes), and subsequently validated with mixed interrater reliability (IRR). We investigated the comparative IRR of this tool in an inpatient cohort to ascertain its practical application in this setting.The patient population was comprised of 44 ADR drug pairs drawn from an observational prospective cohort of patents with ADR attending a Weill Cornell Medicine-affiliated tertiary medical Centre in Doha Qatar (Hamad General Hospital). Using the LAAT, and modified Hallas tools, 4 independent raters (2 Clinical Pharmacologists, and 2 General Physicians) assessed and scored the 44 ADR-drug pairs. Agreement proportions between the rating pairs were evaluated as well individual/overall kappa statistics and intraclass correlation coefficients. We evaluated the weight of each of the 7 questions on the LAAT tool to ascertain its determinative role.Across 44 ADR-drug pairs, the overall median Fleiss kappa using the LAAT, and modified Hallas tools were 0.67 (interquartile range (IQR) 0.55, 0.76), 0.36 (IQR, 0.23-0.71) respectively. The overall percentage pairwise agreement with the LAAT and modified Hallas tools were 78.5%, and 62.2% respectively. Exact pairwise agreement occurred in 37 out of 44 (range 0.71-1), and 27 of 44 (0.53-0.77) ADR-drug pairs using the LAAT and modified Hallas tools respectively. Using the LAAT tool, the overall intraclass correlation coefficient was 0.68 (CI 0.55, 0.79), and 0.37 (CI 0.22, 0.53) with the modified Hallas tool.We report a higher proportion of "possible" and "definite" avoidability outcomes of adverse drug reactions compared with the modified Hallas, or that reported by developers of the LAAT tool. Although initially developed for research purposes, our report has suggested for the first time a potential applicability of this tool in clinical environment as well.

Indexed as

Adverse Outcome PathwaysAdultAlgorithmsDrug-Related Side Effects and Adverse ReactionsFemaleHumansInpatientsMaleMiddle AgedObserver VariationProspective StudiesQatarReproducibility of Results

Identifiers

PMID31895800
PMCPMC6946216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.